As RAS mutation was shown to be associated with a shorter PFS in MSI-H/dMMR CRC patients treated with pembrolizumab in first-line setting [34], subgroup analysis according to BRAF, KRAS, and NRAS mutation status is recommended in future studies. This evidence concerns the gene KRAS and colorectal carcinoma.